Old Web
English
Sign In
Acemap
>
Paper
>
MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study
MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study
2017
Daniel Morgensztern
M. Cobo Dols
S. Ponce Aix
Pieter E. Postmus
Jaafar Bennouna
J. Fischer
Oscar Juan Vidal
David J. Stewart
G. Fasola
J. Weaver
M. Wolfsteiner
T.J. Ong
Ramaswamy Govindan
Keywords:
Nab-paclitaxel
Pathology
Oncology
Internal medicine
Medicine
second line treatment
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]